Science
Mechanism of Action
This compound's mechanism is rooted in its therapeutic design. The 'phosphorothioate' (PS) modification, involving a sulfur atom substitution in the RNA backbone, significantly enhances its stability against nuclease degradation in biological environments and increases its hydrophobicity. Conjugation with 'cholesterol' further amplifies cellular internalization and improves tissue distribution, enabling more effective delivery of therapeutic oligonucleotides to target cells and organs, such as the liver. Its primary function is to optimize stability and cellular entry for drug-like nucleic acids, not to exert direct cosmetic effects.
Research
Clinical Evidence
Insufficient-data confidenceN/A
Key findings
- 01 In rats, cholesterol-conjugated phosphorothioate oligodeoxynucleotides demonstrated approximately a 2-fold increase in liver accumulation compared to non-conjugated counterparts, indicating enhanced cellular uptake by parenchymal, Kupffer, and endothelial cells.
- 02 Asymmetric, phosphorothioate-modified, cholesterol-conjugated siRNAs facilitated rapid cellular internalization and efficient mRNA silencing in cultured cells and in vivo. The phosphorothioate modification primarily contributed to functional silencing efficacy through enhanced stability, rather than merely increased uptake.
- 03 Cholesterol-conjugated oligonucleotides are utilized in the development of antifibrotic skin therapeutics (e.g., OLX10010, an asymmetric interfering RNA targeting connective tissue growth factor), which is currently undergoing phase 2a clinical trials as a drug, not a cosmetic ingredient.
Transparency
Dusting Analysis
As SH-DS PHOSPHOROTHIOATE RNA-2 CHOLESTEROL is not a recognized cosmetic ingredient, a dusting analysis in the context of skincare formulation is not applicable.
The Formula
Formulation
Stability
Phosphorothioate modifications are specifically engineered to impart enhanced metabolic stability to oligonucleotides, safeguarding them against exonuclease degradation in vivo. Cholesterol conjugation further contributes to overall stability and improved pharmacokinetics. While stability assays for modified oligonucleotides may employ buffer conditions such as 50 mM Tris–HCl (pH 7.2), specific optimal pH ranges for stability in a cosmetic formulation are not available.
Conflicts
- High concentrations of phosphorothioate oligonucleotides (e.g., those with a chain length exceeding 15 units) have been shown to inhibit human DNA polymerases and RNase H activities in in vitro experiments.
- Potential for sequence- and structure-dependent cytotoxicity exists, primarily due to non-specific interactions with cellular proteins, especially in the case of single-stranded oligonucleotides that can form stable hairpin structures. These observations stem from therapeutic contexts and are not directly applicable to cosmetic formulation concerns.
Safety
Safety Profile
Information regarding the cosmetic safety of SH-DS PHOSPHOROTHIOATE RNA-2 CHOLESTEROL is completely absent, with no available reviews or assessments by bodies such as CIR, SCCS, or FDA for skincare applications. Safety considerations for phosphorothioate-modified oligonucleotides are documented solely within a *therapeutic* framework, indicating potential concerns like toxicity, reduced specificity, and off-target effects, particularly at elevated concentrations or with specific structural conformations. For example, phosphorothioate oligonucleotides longer than 15 units have been observed to inhibit human DNA polymerases and RNase H in vitro. These are drug-related safety concerns and cannot be directly translated to cosmetic skincare safety.
Your Skin
Skin Compatibility
Our Assessment
Verdict
SH-DS PHOSPHOROTHIOATE RNA-2 CHOLESTEROL has no recognized applications or safety data in the cosmetic skincare industry, being exclusively associated with therapeutic and research contexts.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources